Retinal Cell Promoter Miniaturization for AAV Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing AAV-based gene therapy for retinal diseases is limited by the small packaging capacity of AAV vectors (4.7 kb) and the lack of cell-specific promoters, leading to insufficient efficacy and potential side effects due to non-specific gene expression in retinal cells.
Innovation Solution
Development of a retinal cell-specific promoter of 100 to 400 nucleotides in length, with at least 90% identity to SEQ ID NO: 6 or SEQ ID NO: 7, and an expression cassette that includes enhancers, enabling high-level gene expression in retinal cells, particularly photoreceptor cells, while reducing vector size.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If endogenous promoters are used for retinal cell-specific gene expression, then tissue specificity is improved, but the vector size exceeds AAV packaging capacity
Solution Approach 1:
The invention extracts only the essential core promoter sequences from the full-length endogenous promoters (GRK1 and PDE6B), removing non-essential regions while retaining the ability to drive retinal cell-specific expression. This extraction allows the promoter to fit within AAV packaging capacity while maintaining tissue specificity.
Solution Approach 2:
The invention creates localized promoter sequences with specific nucleotide compositions and lengths (100-400 bp) that are optimized for retinal cell expression. By focusing on the critical local regions of the promoter rather than using the entire promoter sequence, the invention achieves both size reduction and maintained functionality.
2Quantity of substance
If universal promoters are used to accommodate gene size, then vector packaging capacity is improved, but cell-specific expression efficacy deteriorates
Solution Approach 1:
The invention uses locally optimized promoter sequences (100-400 bp) derived from retinal-specific genes that are tailored to drive expression specifically in retinal cells. These localized sequences provide both the size efficiency needed for AAV packaging and the cell-specificity required for effective gene therapy.
Solution Approach 2:
The invention changes the parameters of the promoter sequences by optimizing their length (100-400 bp), nucleotide composition, and structural characteristics to achieve both compact size for AAV packaging and high-level retinal cell-specific expression. This parameter optimization allows simultaneous achievement of packaging efficiency and expression specificity.
3Power
If full-length endogenous promoters are used, then expression level is improved, but vector design complexity increases
Solution Approach 1:
The invention extracts only the essential promoter regions (100-400 bp) required for retinal cell-specific expression, removing redundant sequences. This extraction simplifies vector design while maintaining high-level gene expression capability in the target cells.
Solution Approach 2:
The invention segments the full-length endogenous promoters into smaller, functional units (core promoter sequences of 100-400 bp) that can be independently optimized and assembled into AAV vectors. This segmentation reduces vector design complexity while preserving expression functionality.
Data Source
Figure 1
Figure 2A~2B
Figure 3A~3B
AI summary
The present invention relates to a promoter for gene expression in retinal cells, and a vector system comprising same. The promoter for gene expression in retinal cells and the vector system including same according to the present invention have a minimal unit for promoter activity and, unlike existing known promoters in retinal cells, maintain a high level of expression of a target gene, and thus can be used to maximize the expression of the target protein in retinal cells.